Home - Ophiomics

Developing Dx tools for Precision Liver Medicine

Genomics, Bioinformatics and AI at the service of better liver health

Ophiomics- Precision Medicine

Ophiomics is an ISO 13485 and ISO 9001 certified, clinical-stage Medtech company developing cutting-edge diagnostic products integrating bioinformatics, artificial intelligence and genomics in support of diagnostic, prognostic, treatment selection and clinical follow-up in precision liver medicine.

Vision & Mission

Our vision: To lead the world in liver diagnostics and transform the future of healthcare.

Our Mission: We are committed to revolutionizing liver diagnostics worldwide by leveraging the power of AI and genomics to develop a cutting-edge portfolio of technology-driven, cost-effective products with a massive global impact, significantly enhancing health outcomes.

Actionable

We create practical tools to empower clinicians’ decisions at crucial stages in the liver disease patient journey, where preventative or curative interventions are possible.

Novel

We leverage the power of genomics and Machine Learning to discover novel biomarkers that address unmet clinical needs.

Integrative

We integrate biomarkers and clinical variables through cutting-edge machine-learning algorithms, creating solutions to support clinicians’ decisions.

Accessible

Our end-products – IVD medical devices – are designed to seamlessly integrate into routine clinical practice, ensuring accessibility and ease of adoption

Collaborative

We value partnerships with clinicians, academia, patients, and companies, to build upon and advance our approaches, seeking improved outcomes for all.

Leadership

Executive team

Jose Leal, PhD (CEO)

José Pereira Leal, PhD, is an Innovator, Scientist, Entrepreneur and medtech and precision medicine enthusiast. A bioinformatician with close to 30 years professional experience, having broad and impactful scientific experience at leading Europe, UK and USA institutions, a leader of research infrastructures and a serial entrepreneur in the areas of biodefense, drug development, clinical diagnostic services and medtech. His personal motto is “better life through technology”.

Joana Vaz, PhD (CSO)

Joana Cardoso Vaz, PhD, is a cancer genomics specialist, with extensive experience in collaborating with clinicians, spanning the journey from biomarker discovery to clinical diagnosis. Her credentials include an MSc in Human Genetics from the School of Medicine of the University of Lisbon (Portugal) and a PhD in Biomedical Sciences from the University of Leiden (Netherlands). Her impactful work encompasses diverse areas within cancer genomics for more than 20 years in academia, and she has led the establishment of a pioneering platform for clinical testin in precision oncology, pioneering for example ccfRNA sequencing in the clinical context. Driven by innovation, she strives to apply her technical knowledge to invent new medical products that can enhance and ultimately save the lives of cancer patients.

Sérgio Faria (CFO)

Sérgio Faria, MBA, is an economist and seasoned entrepreneur with over 30 years of experience across the energy, automotive, and life sciences sectors. As CFO of Ophiomics, he leads the company’s financial strategy, capital raising, and investor relations, ensuring scalable and sustainable growth aligned with Ophiomics’ mission to transform precision medicine through AI-powered diagnostics. Having founded and managed multiple Contract Research Organizations (CROs), he has deep expertise in clinical development and the journey from scientific discovery to market. Sérgio combines strategic financial leadership with a focus on innovation, bridging science, business, and technology to drive global expansion.

Board of Directors

Team

Advisors

Christophe Duvoux

Hepatology - FR

Marina Berenguer

Hepatology - ES

Hugo Pinto Marques

HepatoBiliary Surgery - PT

Ana Sofia Carvalho

Ethics - PT

Jean-Pierre Hermet

In Vitro Diagnostics - FR

Ophiomics

Our history

Ophiomics was founded in 2015 by José Pereira Leal and Joana Cardoso Vaz. Initially it was a clinical testing laboratory focused in oncology, that pioneered, in collaboration with Centro de Medicina Laboratorial Germano de Sousa, the routine somatic sequencing, liquid biopsies, and high throughput sequencing for cancer genetics in Portugal. The yearn to pursue innovation by both founders led to the development of a new biomarker-based algorithm to stratify liver cancer patients for curative-intent liver transplantation in collaboration with the transplant surgeon Hugo Pinto Marques. This paved the way for the launch of Ophiomics (2.0) - a company focused on developing innovative AI-assisted In Vitro Diagnostics Medical Devices - funded by the first generation of the ultra-competitive EIC Accelerator grants. Two and a half years later, we launched ou first product, HepatoPredict. This was just the beginning!

Ophiomics

Precision Medicine

The name “Ophiomics” reflects our origins and the cutting-edge technology we develop to advance the medical field. “OPHI” is inspired by the ancient Greek word for serpent, a known symbol for medicine, and by the name of the region where our company was born, Ophiussa, the mythical name for the region where modern-day Portugal is located. The suffix “OMICS” embodies our focus on data analysis and high-throughput technologies, like genomics and transcriptomics.

Technology

In our quest to make precision medicine a reality, we developed re-usable Dx-oriented technological platforms (and some other simpler solutions) that enable and facilitate our development of new products and reduce the industrialisation and logistic uncertainties.

Data and AI

All our end products incorporate machine learning models that enable us to extract more and better information from data, and to integrate diverse data types, such as clinical and biomarker-based data.

R&D

New in vitro diagnostics medical devices are essential components of a precision medicine to improve early detection, diagnosis, and treatment, ultimately leading to better patient outcomes. We developed a unique approach to biomarker discovery and development centred around addressing unmet medical needs and minimising technical, clinical, and commercial uncertainties, enabling us to maximize the chances of bringing impactful products to market and positively impacting patients’ lives.